Cogstate (ASX:CGS): FY26 Results and September-Quarter Clinical Trial Contracts

Aditi Sarkar

03 November 2026 05:53 PM AEDT

Cogstate (ASX:CGS): FY26 Results and September-Quarter Clinical Trial Contracts

Image Source: Shutterstock

You are reading a free article with opinions that may differ from the recommendation given by Kalkine in its paid research reports. Become a Kalkine member today to get access to our research reports, in-depth technical and fundamental research. Learn more

Start Your Free Trial Now!

Highlights

FY26 Revenue reached USD 60.9 million and EBITDA was USD 18.3 million.
The FY26 Annual Report recorded USD 89.0 million in new net sales contracts.
September-quarter FY27 net sales contracts totalled USD 25.1 million.
Contracted revenue, including revenue recognised in the quarter, stood at USD 143.7 million at 30 September 2026.

Cogstate Limited (ASX:CGS) provides cognitive assessment technology and specialist endpoint services to clinical trials, alongside digital cognitive assessment products used in healthcare. On 3 November 2026, the stock finished the session at AUD 3.37. The company’s recent 2026 disclosures bring its operational priorities and financial measures into focus.

FY26 Financial Performance

Cogstate (ASX:CGS) reported FY26 revenue of USD 60.9 million compared with USD 53.1 million for FY25. FY26 EBITDA was USD 18.3 million, while net profit after tax was approximately USD 11.9 million. Its Clinical Trials division generated approximately USD 58.4 million in annual revenue, making it the main reported contributor. Healthcare revenue was approximately USD 2.5 million.

Contract execution and revenue recognition are different events in the group’s Business model. Trials can run over several reporting periods, and the timing of sponsor activity, deployment and service delivery affects when contracted work becomes recognised revenue. Cogstate reported 90 new trial starts in FY26 compared with 35 in FY25, while ongoing trials reached 171 at year-end.

September-Quarter Contracts and Delivery

The October 2026 business update recorded USD 25.1 million of new contracts during the September quarter. At 30 September, contracted revenue including amounts already recognised in the quarter totalled USD 143.7 million, compared with USD 101.8 million on the comparable basis a year earlier. Contracted FY27 revenue, including first-quarter recognised revenue, was USD 56.8 million.

Five Phase 3 mood-disorder studies across two customers accounted for more than 80% of the quarter’s new sales contract value, according to Cogstate. This makes the mix of wins an important qualification to the quarterly total: individual large programs can materially influence contract values. Management has also discussed Investment in technology and automation, which introduces implementation spending alongside potential workflow changes.

Operating Risks and Financial Context

For Cogstate Limited (ASX:CGS), the most useful assessment separates business activity from financial outcomes. The distinction between an announced milestone and a completed commercial or financial outcome is important. Management disclosures can describe objectives, progress and planned next steps, but reported results provide the evidence of what was achieved during a particular period. Comparing successive reporting periods on the same accounting or operational basis helps avoid misleading conclusions. Sector-wide conditions can influence a business without demonstrating that they caused a particular daily share-price movement.

What to Watch Next

Important areas for the next published updates include clinical-trial starts, conversion of contracts into revenue, customer concentration in large studies and planned technology expenditure. Each may affect the interpretation of the company’s progress, but none should be treated as a forecast of profitability, trial success or share-price performance. The timing of disclosures also matters because the information available at 3 November 2026 may not cover every development later in the financial year.

Key Insights

Cogstate Limited (ASX:CGS) has reported developments during 2026 that relate to its operating model, financial resources and management priorities. Its latest disclosed measures need to be interpreted on their stated reporting basis. The next company updates may clarify the pace of activity, associated costs and the extent to which operational progress translates into recognised revenue, clinical evidence or available cash, as relevant to the business.

Download Free Report – Explore 3 Stock Ideas & Industry Insights

Unlock 3 stock ideas and key industry insights in our free report. This information is general in nature and does not consider your personal objectives, financial situation, or needs. It is not financial advice.

All investments involve risk—consider independent advice before making any investment decisions.

View 3 Research Reports

Disclaimer:

This article (“Article”) has been prepared by Kalkine Pty Limited (ABN 34 154 808 312) (Australian financial services licence number 425376) (“Kalkine”) and its related bodies corporate who are authorised to provide general financial product advice. Kalkine.com.au and its associated pages are published by Kalkine.

Any information/advice provided in this article is general in nature and does not take into account your objectives, financial situation or needs. You should therefore consider whether the information is appropriate for your objectives, financial situation and needs before acting upon it.

There may be a Product Disclosure Statement, Information Memorandum or other offer document (“Offer Document”) for the securities or other financial products referred to in Kalkine articles. You should obtain a copy of the Offer Document and consider it before making any decision about whether to acquire the security or financial product.

Kalkine strongly recommends that you seek advice from a financial adviser, stockbroker or other professional (including taxation and legal advice) before acting on any advice/information in this Article or on the Kalkine website. Not all investments are appropriate for all people.

The information in this Article and on Kalkine website has been prepared from a wide variety of sources, which Kalkine, to the best of its knowledge and belief, considers accurate. Kalkine has made every effort to ensure the reliability of the information contained in its articles (including this Article), newsletters and websites. All information represents our views at the date of publication and may change without notice.

The information in this Article does not constitute an offer to sell securities or other financial products or a solicitation of an offer to buy securities or other financial products.

Kalkine does not issue, sell or deal in any financial products.

This Article may contain information on past performance of particular investments. Please note past performance is neither an indicator nor a guarantee of future performance.

To the extent permitted by law, and excluding any dishonesty or gross negligence by Kalkine, Kalkine disclaims and excludes all liability for any direct, indirect, implied, punitive, special, incidental or other consequential loss or damage arising from the use of or reliance on this Article, the Kalkine website and any information published on the Kalkine website without any warranties or representations by Kalkine to you. To the extent the law prohibits or limits this exclusion, Kalkine limits its liability to the resupply of services.

Please also read our Terms & Conditions and Financial Services Guide for further information.

Employees and/or associates of Kalkine and its related entities may hold interests in the securities or other financial products covered in this Article or on the Kalkine website. Any such employees and associates are required to comply with certain safeguards, procedures and disclosures as required by law.

Some of the images/music that may be used in the Article are copyright to their respective owner(s). Kalkine does not claim ownership of any of the pictures displayed/music used in the Article unless stated otherwise. The images/music that may be used in the Article are taken from various sources on the internet, including paid subscriptions or are believed to be in public domain. We have used reasonable efforts to accredit the source wherever it was indicated or was found to be necessary.

Kalkine Media Pty Ltd, an affiliate of Kalkine Pty Ltd, may have received, or be entitled to receive, financial consideration in connection with providing information about certain entity(s) covered on its website.